Levofloxacin: Nursing Drug Guide, Tendon Injury & QT Risk
Healthcare medication guide: before every once-daily dose, screen for fluoroquinolone tendon injury (especially age over 60 and concurrent prednisone), ECG/QT risk with hypokalemia or Class IA/III antiarrhythmics, myasthenia gravis history, and separation from magnesium or aluminum antacids—levofloxacin can cause irreversible tendon rupture, neuropathy, and serious CNS toxicity.
Levofloxacin and other fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together—including tendinitis and tendon rupture (most often the Achilles tendon), peripheral neuropathy, and central nervous system effects. Risk is highest in patients over 60, those taking corticosteroids, and patients with kidney, heart, or lung transplants. Labeling also warns of QT interval prolongation with uncorrected hypokalemia or QT-prolonging drugs. Avoid levofloxacin in myasthenia gravis. Before every dose, complete medication reconciliation, assess gait and joint complaints, review potassium and ECG risk, and hold plus escalate at the first sign of tendon pain, neuro symptoms, or serious hypersensitivity.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first and each subsequent dose, screen quinolone allergy, tendon and joint symptoms, corticosteroid and transplant risk factors, potassium and QT-prolonging drugs on the MAR, renal function for Table 3 adjustment, and antacid timing. Hold levofloxacin and notify the prescriber or pharmacist for new heel or shoulder pain, confusion or tremor, burning numbness in hands or feet, serious rash, or watery diarrhea with fever.
Most common brand names
Levofloxacin is available as generic tablets and, in some markets, as Levaquin and other brand formulations. FDA tablet labeling includes 250 mg, 500 mg, and 750 mg strengths. Verify route, strength, and whether the order is oral or IV before administration—formulations are not interchangeable without a new prescriber order.
Levofloxacin is the (S)-enantiomer of ofloxacin and a fluoroquinolone, not a penicillin, cephalosporin, or macrolide. Do not confuse it with ciprofloxacin or moxifloxacin during medication reconciliation; allergy documentation must specify quinolone hypersensitivity when present.
Why we give it — Indications
Levofloxacin treats infections caused by susceptible organisms when benefit outweighs fluoroquinolone risks. Nurses commonly see it for urinary tract infection, complicated UTI/pyelonephritis, respiratory infections including pneumonia, skin and soft-tissue infection, chronic bacterial prostatitis, and labeled post-exposure anthrax or plague regimens per prescribing information.
| Use (adults, oral examples) | Typical labeled dose (once daily) | Duration (usual) |
|---|---|---|
| Uncomplicated UTI | 250 mg every 24 hours | 3 days |
| Complicated UTI / acute pyelonephritis | 750 mg every 24 hours | 5 days (750 mg regimen) or 10 days (250 mg regimen per label) |
| Community-acquired pneumonia | 500 or 750 mg every 24 hours | 5–14 days depending on regimen |
| Acute bacterial sinusitis | 750 mg every 24 hours | 5 days (750 mg regimen) or 10–14 days (500 mg regimen) |
| Chronic bacterial prostatitis | 500 mg every 24 hours | 28 days |
On a small screen, swipe or scroll sideways to see the full table.
Labeling reserves levofloxacin for certain uncomplicated UTI, acute bacterial exacerbation of chronic bronchitis, and acute bacterial sinusitis indications when patients have no alternative treatment options, because disabling serious adverse reactions can occur. FDA drug safety communications also advise restricting oral fluoroquinolones for some uncomplicated infections when other options are available. Follow institutional antimicrobial stewardship—nurses escalate concerns when fluoroquinolones are ordered without a clear susceptibility or safety rationale.
How it works
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication in susceptible bacteria. Nursing focus extends beyond coverage: levofloxacin carries class warnings for tendon injury, peripheral neuropathy, CNS toxicity, and QT prolongation—these risks drive hold rules and patient teaching more than the mechanism alone. Levofloxacin may increase the anticoagulant effect of warfarin; monitor INR when co-prescribed per labeling.
Dosing overview
Verify indication, renal function, and route against current prescribing information. Usual adult dosing is 250 mg, 500 mg, or 750 mg once every 24 hours depending on infection (Table 1 in labeling). Adjust when creatinine clearance is below 50 mL/min per Table 3.
Table 3 — Renal dose adjustment (CrCl <50 mL/min, DailyMed)
| Normal dose (q24h) | CrCl 20–49 mL/min | CrCl 10–19 mL/min | Hemodialysis or CAPD |
|---|---|---|---|
| 750 mg | 750 mg every 48 h | 750 mg load, then 500 mg q48h | 750 mg load, then 500 mg q48h |
| 500 mg | 500 mg load, then 250 mg q24h | 500 mg load, then 250 mg q48h | 500 mg load, then 250 mg q48h |
| 250 mg | No adjustment | 250 mg q48h (uncomplicated UTI: no adjustment) | Not specified in the reviewed prescribing information |
On a small screen, swipe or scroll sideways to see the full table.
Pediatrics: Weight-based regimens apply for inhalational anthrax and plague in children ≥6 months; pediatric patients have increased musculoskeletal adverse events—use pharmacy and the full label for weight-based dosing.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for guidance.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Administration with food | May be given without regard to food | Once-daily dosing simplifies MAR—but do not skip renal or QT screening |
| Half-life | ~6–8 hours in adults (labeling) | Prolonged when renal function is reduced—apply Table 3 |
| Antacids / multivalent cations | Reduced absorption when given together | Give levofloxacin at least 2 hours before or 2 hours after magnesium/aluminum antacids, sucralfate, iron, zinc, or didanosine products per labeling |
| Elimination | Primarily renal | Trend basic metabolic panel / creatinine in chronic kidney disease or acute kidney injury |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: levofloxacin, any fluoroquinolone, or product component
- MAR review for QT-prolonging drugs (e.g., Class IA/III antiarrhythmics), warfarin, corticosteroids, and antidiabetic agents (hypo-/hyperglycemia risk per labeling)
- Recent renal function and potassium; ECG/QT history when QT-prolonging co-therapy is present
- History of myasthenia gravis—avoid levofloxacin per labeling
- Gait and joint assessment (tendon risk); mental status baseline for CNS effects
- Scheduled antacids, iron, or sucralfate—plan 2-hour before / 2-hour after separation
Contraindications
- Known hypersensitivity to levofloxacin or other quinolone antibacterials
- Known history of myasthenia gravis (avoid per labeling)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Warfarin | May enhance anticoagulant effect | Monitor prothrombin time/INR closely during concurrent therapy |
| Class IA/III antiarrhythmics | Additive QT prolongation risk | Avoid combination when possible; correct hypokalemia; monitor ECG per prescriber |
| Magnesium/aluminum antacids, iron, calcium, zinc | Reduced levofloxacin absorption | Separate by at least 2 h before or 2 h after levofloxacin |
| NSAIDs | May increase CNS stimulation and seizures | Monitor for tremor, confusion, or seizures—especially with renal impairment |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: May be administered without regard to food per labeling. Maintain adequate hydration to prevent highly concentrated urine (crystalluria reported with quinolones). Use medication administration rights and swallow with water.
- Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, or products with calcium, iron, or zinc
- Independent double-check of warfarin and QT-prolonging combinations on the MAR
- Document administration, fluid intake, and any joint or neuro complaints
- IV levofloxacin: follow institutional IV antibiotic and infusion protocols when ordered
Expected therapeutic response
- Decreasing fever and improving dysuria, urgency, or flank pain when treating susceptible UTI
- Improving respiratory symptoms and white blood cell trend when treating susceptible respiratory infection
- Stable mental status without new confusion, tremor, or insomnia
- No new tendon pain or gait change during or after therapy
- No new QT-related symptoms (syncope, palpitations) when ECG risk factors are present
Red flags — Stop and act
Hold levofloxacin and escalate immediately when serious toxicity is suspected.
- Sudden pain, swelling, or inability to use a joint—possible tendon rupture; rest joint and notify prescriber urgently
- Confusion, hallucinations, tremor, seizure, or suicidal thoughts—CNS toxicity per labeling
- Burning, tingling, or numbness in hands or feet—possible peripheral neuropathy; stop drug to prevent irreversible injury
- Syncope or palpitations with QT-prolonging co-therapy or hypokalemia—evaluate ECG per prescriber
- Signs of hepatitis: jaundice, dark urine, severe abdominal pain
- Angioedema, bronchospasm, or systemic allergic reaction (some after first dose)
- Serious rash or mucosal involvement
- Watery diarrhea, abdominal pain, fever—evaluate for C. difficile colitis
- Worsening weakness or respiratory distress in myasthenia gravis
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, headache, diarrhea, insomnia, constipation, dizziness | Most common reactions ≥3% in trials per labeling | Supportive care; differentiate mild GI upset from CDAD or hepatitis |
| Tendinitis / tendon rupture | Boxed warning; higher risk age >60, steroids, transplant | Stop drug, rest affected limb, urgent prescriber/surgical review |
| CNS effects | Confusion, tremor, seizures; may follow first dose | Stop drug, neurologic assessment, fall precautions |
| Peripheral neuropathy | May be irreversible if continued | Stop at first sensory symptoms; document and notify prescriber |
| QT prolongation / torsade de pointes | Rare; avoid in known QT prolongation and uncorrected hypokalemia | Correct potassium; monitor ECG; hold QT-prolonging co-drugs per prescriber |
| Hepatotoxicity / serious hypersensitivity | Includes fatal cases postmarketing | Stop drug; order liver function tests per prescriber; treat severe reaction per protocol |
| CDAD | Reported with nearly all antibacterials | Isolation precautions per facility; stool studies per order |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
In acute overdosage, labeling states the stomach should be emptied, the patient observed, and appropriate hydration maintained.
Management
Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis per prescribing information. Levofloxacin exhibits a low potential for acute toxicity in animal studies at very high doses. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or toxicology services per facility protocol and local emergency guidance for severe overdose.
Look-alike / sound-alike and error prevention
- Levofloxacin vs Levetiracetam—both “lev-” prefixes; verify drug class (antibiotic vs antiepileptic) on MAR
- Levofloxacin vs ciprofloxacin / moxifloxacin—different fluoroquinolones with different daily doses; confirm strength (250/500/750 mg)
- Once daily vs twice daily—levofloxacin is usually q24h; do not copy ciprofloxacin q12h schedules
- Renal Table 3—dosing errors are common when CrCl drops below 50 mL/min; pharmacy should verify
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Tendon screen | Ask about exercise, steroids, and new heel or shoulder pain at every shift |
| QT / potassium | Flag hypokalemia and amiodarone or sotalol on MAR before giving dose |
| Antacid timing | Chart separation from PPI/antacid/iron—many “given” doses are not absorbed |
| Hydration | Encourage fluids per plan—crystalluria risk with concentrated urine |
| Commonly missed | Continuing levofloxacin after tendon pain; giving with breakfast calcium supplement |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (>60) | Highest tendon rupture risk; greater QT-interval sensitivity with QT-prolonging co-drugs |
| Corticosteroid therapy | Further increased tendon rupture risk—coordinate with prescriber before starting |
| Organ transplant recipients | Labeling identifies kidney, heart, or lung transplant as higher tendon risk |
| Renal impairment (CrCl <50) | Adjust per Table 3; monitor renal function during prolonged therapy |
| Myasthenia gravis | Avoid levofloxacin—postmarketing deaths and ventilatory failure reported |
| Pregnancy | Use only if potential benefit justifies potential risk to the fetus per labeling |
| Lactation | Detected in human milk; serious infant reactions possible—discontinue nursing or drug per labeling decision |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Joint and tendon symptoms, gait, and ability to bear weight
- Mental status, sleep, tremor, or new neurologic complaints
- Renal function and creatinine clearance trend for Table 3 dosing
- Serum potassium and ECG/QT when QT-prolonging drugs are concurrent
- INR or prothrombin time when warfarin is concurrent
- Blood glucose when antidiabetic agents are concurrent (dysglycemia reported)
- GI tolerance, hydration, and stool character
- Infection response: temperature, WBC, urine symptoms, or respiratory status per plan
Document
- Tendon, QT, and interaction screening before first dose
- Antacid or multivalent cation separation education and administration times
- Any held doses with prescriber/pharmacist notification and patient symptoms
- Patient teaching on tendon pain, neuro symptoms, photosensitivity, and severe diarrhea
Patient teaching
- Take exactly as directed once daily unless pharmacy adjusts for renal function; ask how to schedule iron, calcium, or stomach medicines 2 hours apart
- Stop exercising at the first sign of tendon pain, swelling, or inability to move a joint, and contact the prescriber immediately
- Report confusion, tremor, depression, insomnia, numbness, tingling, or burning in hands or feet promptly
- Report watery diarrhea, blood in stool, or severe abdominal pain—even after stopping the antibiotic
- Avoid excessive sunlight or UV exposure—photosensitivity/phototoxicity reported with fluoroquinolones
- Do not share antibiotics; complete the course only if the prescriber continues the drug after safety review
- Breastfeeding: discuss risks and benefits with the prescriber—drug is present in breast milk per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to levofloxacin or any fluoroquinolone
- Known history of myasthenia gravis
- New or worsening tendon pain, swelling, inflammation, or joint weakness
- Confusion, hallucinations, tremor, seizure, or other significant CNS toxicity
- Peripheral neuropathy symptoms (pain, burning, tingling, numbness, weakness)
- Serious allergic reaction, severe rash, or signs of hepatitis
- Watery diarrhea with fever or suspected C. difficile pending evaluation
- Uncorrected hypokalemia or new syncope/palpitations with QT-prolonging co-therapy until prescriber review
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Levofloxacin offers once-daily dosing for susceptible infections—but fluoroquinolone boxed warnings mean nurses must pair administration with tendon, neuro, and QT surveillance, not only infection response.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and Table 3 renal adjustment verified when CrCl <50 mL/min
- Quinolone allergy and myasthenia gravis contraindication reviewed on MAR
- Warfarin, QT-prolonging drugs, corticosteroids, and antidiabetic agents flagged
- Antacid, iron, calcium, or zinc products scheduled outside the 2-hour before / 2-hour after window
2. Safety badge
Fluoroquinolone — tendon, CNS, neuropathy, and QT screening requiredTreat tendon and QT risk with the same rigor as institutional high-alert workflows even when the product is not on a formal high-alert list in every facility.
3. Hold and question rules
- Any new heel or shoulder pain → hold next dose and notify prescriber same shift
- Potassium 3.2 mEq/L with amiodarone on MAR → hold until electrolyte and ECG plan clarified
- Patient on prednisone with new gait change → urgent prescriber review before further doses
4. Critical teach-back questions
- “What joint symptoms should you report immediately?” (Patient should name pain, swelling, or inability to use a joint and stopping exercise.)
- “How should you take antacids or iron with this antibiotic?” (Patient should describe separating doses by at least 2 hours before or after.)
5. Care coordination
Pharmacist: Table 3 renal adjustment, warfarin/INR monitoring, QT and potassium review, antacid timing
Prescriber: Alternative antibiotic when fluoroquinolone risk outweighs benefit; tendon or neuropathy management
🧠 Quick mental checklist
- Is the patient over 60, on steroids, or post-transplant?
- Are warfarin, amiodarone/sotalol, or other QT-prolonging drugs on the MAR?
- What is creatinine clearance—is Table 3 adjustment reflected on the MAR?
- Is potassium normal and were antacids or iron separated by 2 hours?
- Any new tendon pain, confusion, tremor, numbness, syncope, or watery diarrhea?
Levofloxacin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for levofloxacin tendon and QT safety using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), potassium/QT trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Levofloxacin 750 mg PO once daily (day 2 of community-acquired pneumonia regimen)
- Prednisone 40 mg PO daily — given 0800
- Amiodarone 200 mg PO daily — given 0800
- Potassium chloride 40 mEq PO — held yesterday for K 3.2
- Calcium carbonate 500 mg PO with breakfast — given 0730
- Potassium 3.2 mEq/L (was 3.6 yesterday)
- Creatinine 1.5 mg/dL (baseline 1.1); estimated CrCl ~38 mL/min per pharmacy
- INR 2.8 on warfarin 5 mg daily (target often 2–3 per facility)
- WBC trending down; chest X-ray improving per team
- BP 118/72, HR 96, temp 37.1 °C, SpO2 94% on 2 L nasal cannula
- Telemetry: QTc 512 ms (baseline 468 ms)
- Patient reports mild dizziness when standing
- 68-year-old reports sharp pain behind left heel when walking; mild swelling noted
- States “legs feel weak” since starting antibiotic yesterday
- Calcium carbonate taken with breakfast 40 minutes before scheduled levofloxacin
- Pharmacy note: “CrCl <50—verify Table 3 dose; QT and K review”
Answer key & rationale
Frequently asked questions
Why are tendon injury and QT prolongation the main nursing safety concerns with levofloxacin?
Prescribing information carries a boxed warning for disabling and potentially irreversible serious reactions including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects. Levofloxacin is also associated with QT interval prolongation and rare torsade de pointes; risk increases with known QT prolongation, uncorrected hypokalemia, and Class IA or III antiarrhythmics.
When should a nurse hold levofloxacin?
Hold for hypersensitivity to levofloxacin or any quinolone; avoid in myasthenia gravis; stop for new tendon pain, swelling, or inability to use a joint; CNS toxicity such as confusion, tremor, or seizures; peripheral neuropathy symptoms; serious rash or hepatitis; watery diarrhea with fever suggesting C. difficile; or when QT-prolonging co-therapy and hypokalemia are not corrected until prescriber or pharmacist review.
How is levofloxacin dosed when creatinine clearance is below 50 mL/min?
For creatinine clearance at or above 50 mL/min, use the usual once-daily dose per indication. When creatinine clearance is below 50 mL/min, adjust dose and interval per Table 3 in prescribing information—for example, 750 mg every 48 hours when CrCl is 20 to 49 mL/min, with further reduction at lower clearance and after dialysis per the label tables.
What adverse effects matter most for nurses?
Priority nursing concerns include tendinitis and tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, serious hypersensitivity and hepatotoxicity, C. difficile-associated diarrhea, myasthenia gravis exacerbation, and common reactions such as nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Is levofloxacin safe in pregnancy and breastfeeding?
Labeling states levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Levofloxacin has been detected in human breast milk; because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
References
- U.S. National Library of Medicine. Levofloxacin tablet — Full prescribing information. DailyMed (setid 95149cfb-1a71-42b7-b50d-9a2e94334339).https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95149cfb-1a71-42b7-b50d-9a2e94334339
- U.S. Food and Drug Administration. FDA advises restricting use of oral fluoroquinolone antibiotics for certain uncomplicated infections. Drug Safety Communication.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-use-oral-fluoroquinolone-antibiotics-certain
- Drugs and Lactation Database (LactMed). Levofloxacin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501002/
- U.S. National Library of Medicine. Levofloxacin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a697040.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.